Cladribine (oral) and Peginterferon beta-1a
Determining the interaction of Cladribine (oral) and Peginterferon beta-1a and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia. In a phase 2 study of patients experiencing active relapsing multiple sclerosis, lymphopenia was reported significantly more in patients who received interferon-beta and cladribine (40.3%) versus patients who received interferon-beta alone (0%). MANAGEMENT: Concomitant use of cladribine and beta interferons is not recommended. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN-â in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0 View all 4 references
Professional:GENERALLY AVOID: The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia. In a phase 2 study of patients experiencing active relapsing multiple sclerosis, lymphopenia was reported significantly more in patients who received interferon-beta and cladribine (40.3%) versus patients who received interferon-beta alone (0%).
MANAGEMENT: Concomitant use of cladribine and beta interferons is not recommended.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN-â in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: Cladribine
Generic Name: peginterferon beta-1a
Brand name: Plegridy, Plegridy Pen, Plegridy Pen Starter Pack, Plegridy Starter Pack
Synonyms: Peginterferon Beta-1a
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine (oral)-Peginterferon beta-1a Subcutaneous
- Cladribine (oral)-PegIntron
- Cladribine (oral)-Pegloticase
- Cladribine (oral)-Pegloticase Intravenous
- Cladribine (oral)-Pegvaliase
- Cladribine (oral)-Pegvaliase-pqpz
- Peginterferon beta-1a-Cladribine injection
- Peginterferon beta-1a-Cladribine Intravenous
- Peginterferon beta-1a-Cladribine Tablets
- Peginterferon beta-1a-Claforan
- Peginterferon beta-1a-Claforan in D5W
- Peginterferon beta-1a-Claravis